Literature DB >> 16534880

Serological pattern "anti-HBc alone": characterization of 552 individuals and clinical significance.

Antje Knöll1, Arndt Hartmann, Harald Hamoshi, Karin Weislmaier, Wolfgang Jilg.   

Abstract

AIM: To investigate the prevalence and clinical significance of "anti-HBc alone" in an unselected population of patients and employees of a university hospital in southern Germany.
METHODS: All individuals with the pattern "anti-HBc alone" were registered over a time span of 82 mo. HBV-DNA was measured in serum and liver samples, and clinical charts were reviewed.
RESULTS: Five hundred and fifty two individuals were "anti-HBc alone" (of 3004 anti-HBc positive individuals; 18.4%), and this pattern affected males (20.5%) more often than females (15.3%; P<0.001). HBV-DNA was detected in serum of 44 of 545 "anti-HBc alone" individuals (8.1%), and in paraffin embedded liver tissue in 16 of 39 patients tested (41.0%). There was no association between the detection of HBV genomes and the presence of biochemical, ultrasonic or histological signs of liver damage. Thirty-eight "anti-HBc alone" patients with cirrhosis or primary liver carcinoma had at least one additional risk factor. HCV-coinfection was present in 20.4% of all individuals with "anti-HBc alone" and was the only factor associated with a worse clinical outcome.
CONCLUSION: In an HBV low prevalence area, no evidence is found that HBV alone causes severe liver damage in individuals with "anti-HBc alone". Recommendations for the management of these individuals are given.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16534880      PMCID: PMC4124438          DOI: 10.3748/wjg.v12.i8.1255

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  23 in total

1.  Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy.

Authors:  M S Czuczman; A J Grillo-López; C A White; M Saleh; L Gordon; A F LoBuglio; C Jonas; D Klippenstein; B Dallaire; C Varns
Journal:  J Clin Oncol       Date:  1999-01       Impact factor: 44.544

2.  NAT for HBV and anti-HBc testing increase blood safety.

Authors:  W Kurt Roth; Marijke Weber; Detlev Petersen; Christian Drosten; Sylvia Buhr; Walid Sireis; Wolfgang Weichert; Doris Hedges; Erhard Seifried
Journal:  Transfusion       Date:  2002-07       Impact factor: 3.157

3.  Prevalence of markers of hepatitis B in the adult German population.

Authors:  W Jilg; B Hottenträger; K Weinberger; K Schlottmann; E Frick; A Holstege; J Schölmerich; K D Palitzsch
Journal:  J Med Virol       Date:  2001-02       Impact factor: 2.327

4.  Frequency and load of hepatitis B virus DNA in first-time blood donors with antibodies to hepatitis B core antigen.

Authors:  Holger Hennig; Ines Puchta; Jürgen Luhm; Peter Schlenke; Siegfried Goerg; Holger Kirchner
Journal:  Blood       Date:  2002-10-01       Impact factor: 22.113

5.  Low frequency of human polyomavirus BKV and JCV DNA in urothelial carcinomas of the renal pelvis and renal cell carcinomas.

Authors:  Antje Knöll; Robert Stoehr; Wolfgang Jilg; Arndt Hartmann
Journal:  Oncol Rep       Date:  2003 Mar-Apr       Impact factor: 3.906

6.  Reactivation of resolved hepatitis B virus infection after allogeneic haematopoietic stem cell transplantation.

Authors:  A Knöll; S Boehm; J Hahn; E Holler; W Jilg
Journal:  Bone Marrow Transplant       Date:  2004-05       Impact factor: 5.483

7.  Natural history of hepatitis B virus infection in renal transplant recipients--a fifteen-year follow-up.

Authors:  G Dusheiko; E Song; S Bowyer; M Whitcutt; G Maier; A Meyers; M C Kew
Journal:  Hepatology       Date:  1983 May-Jun       Impact factor: 17.425

8.  Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection.

Authors:  Teresa Pollicino; Giovanni Squadrito; Giovanni Cerenzia; Irene Cacciola; Giuseppina Raffa; Antonio Craxi; Fabio Farinati; Gabriele Missale; Antonina Smedile; Claudio Tiribelli; Erica Villa; Giovanni Raimondo
Journal:  Gastroenterology       Date:  2004-01       Impact factor: 22.682

9.  Serial studies of hepatitis-associated antigen and antibody in patients receiving antitumor chemotherapy for myeloproliferative and lymphoproliferative disorders.

Authors:  J R Wands; C M Chura; F J Roll; W C Maddrey
Journal:  Gastroenterology       Date:  1975-01       Impact factor: 22.682

10.  Epidemiological and clinical burden of chronic hepatitis B virus/hepatitis C virus infection. A multicenter Italian study.

Authors:  Giovanni B Gaeta; Gianfranca Stornaiuolo; Davide F Precone; Salvatore Lobello; Maria Chiaramonte; Tommaso Stroffolini; Giuseppe Colucci; Mario Rizzetto
Journal:  J Hepatol       Date:  2003-12       Impact factor: 25.083

View more
  19 in total

Review 1.  Isolated anti-HBc: The Relevance of Hepatitis B Core Antibody-A Review of New Issues.

Authors:  Tiffany Wu; Ryan M Kwok; Tram T Tran
Journal:  Am J Gastroenterol       Date:  2017-10-31       Impact factor: 10.864

2.  Isolated Hepatitis B Core Antibody Status Is Not Associated With Accelerated Liver Disease Progression in HIV/Hepatitis C Coinfection.

Authors:  Audrey L French; Anna Hotton; Mary Young; Marek Nowicki; Michael Augenbraun; Kathryn Anastos; Eric Seaberg; William Rosenberg; Marion G Peters
Journal:  J Acquir Immune Defic Syndr       Date:  2016-07-01       Impact factor: 3.731

3.  Novel double-antigen sandwich immunoassay for human hepatitis B core antibody.

Authors:  An Li; Quan Yuan; Zhiyin Huang; Jian Fan; Ruyi Guo; Bin Lou; Qin Zheng; Shengxiang Ge; Yixin Chen; Zhijun Su; Anthony E T Yeo; Yu Chen; Jun Zhang; Ningshao Xia
Journal:  Clin Vaccine Immunol       Date:  2010-01-27

4.  Current use of hepatitis B immune globulin for prevention of de novo hepatitis B in recipients receiving anti-HBc-positive livers.

Authors:  Jen-Jung Pan; Nirav Thosani; Victor I Machicao; Michael B Fallon
Journal:  Hepatol Int       Date:  2011-01-22       Impact factor: 6.047

5.  [4. Austrian consensus-statement for diagnosis and therapy of hepatitis B 2009].

Authors:  Markus Peck-Radosavljevic; Johann Deutsch; Peter Ferenci; Ivo Graziadei; Harald Hofer; Heidemarie Holzmann; Wolf-Dietrich Huber; Herman Laferl; Andreas Maieron; Rudolf Stauber; Wolfgang Vogel
Journal:  Wien Klin Wochenschr       Date:  2010-05-04       Impact factor: 1.704

6.  Responses to hepatitis B vaccine in isolated anti-HBc positive adults.

Authors:  Jun Yao; Wen Ren; Yongdi Chen; Zhenggang Jiang; Lingzhi Shen; Huan Shan; Xuewei Dai; Jing Li; Ying Liu; Yan Qiu; Jingjing Ren
Journal:  Hum Vaccin Immunother       Date:  2016-04-11       Impact factor: 3.452

7.  Isolated hepatitis B core antibody is associated with HIV and ongoing but not resolved hepatitis C virus infection in a cohort of US women.

Authors:  Audrey L French; Eva Operskalski; Marion Peters; Howard D Strickler; Phyllis C Tien; Gerald B Sharp; Marshall J Glesby; Mary Young; Michael Augenbraun; Eric Seaberg; Andrea Kovacs
Journal:  J Infect Dis       Date:  2007-04-05       Impact factor: 5.226

8.  Low prevalence of HBV DNA in the liver allograft from anti-HBc-positive donors: a single-center experience.

Authors:  Jen-Jung Pan; Seh-Hoon Oh; Consuelo Soldevila-Pico; David R Nelson; Chen Liu
Journal:  Clin Transplant       Date:  2011 Jan-Feb       Impact factor: 2.863

9.  Clinical significance of "anti-HBc alone" in human immunodeficiency virus-positive patients.

Authors:  Ma Teresa Pérez-Rodríguez; Bernardo Sopeña; Manuel Crespo; Alberto Rivera; Teresa González del Blanco; Antonio Ocampo; César Martínez-Vázquez
Journal:  World J Gastroenterol       Date:  2009-03-14       Impact factor: 5.742

10.  Long-term serologic follow-up of isolated hepatitis B core antibody in HIV-infected and HIV-uninfected women.

Authors:  Audrey L French; Michael Y Lin; Charlesnika T Evans; Lorie Benning; Marshall J Glesby; Mary A Young; Eva A Operskalski; Michael Augenbraun; Marion Peters
Journal:  Clin Infect Dis       Date:  2009-07-01       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.